EC safety data sheet
Trade name: Bicalutamide 50 mg Film-coated tablets / Bicalutamide 150 mg Film
Identification of the substance/preparation and of the company/undertaking Identification of the substance or preparation Trade name Bicalutamide 50 mg Film-coated tablets / Bicalutamide 150 mg Film coated tablets Use of the substance/preparation Company/undertaking identification
medac Gesellschaft für klinische Spezialpräparate mbH Fehlandtstrasse 3 20354
Information provided by / telephone
Wedel site: Tel: +49 (4103)-8006-0; Fax: +49 (4103)-8006-100
Emergency telephone
+49(0)551 / 19240 {Giftinformationszentrum Nord (GIZ-Nord)} (Service in english)
Advice on Safety Data Sheet Hazards identification Hazard symbols Particular information pertaining specific risk for human / environment
The product does not require a hazard warning label in accordance with Directive 1999/45/EC. No special hazards have to be mentioned. But please observe the information given in this safety data sheet.
Composition / information on ingredients Chemical characterization Additional ingredients: bicalutamide (INN) First aid measures General information
In case of persisting adverse effects, consult a physician. Change contaminated, saturated clothing.
After inhalation
Remove affected person from the immediate area. Ensure supply of fresh air.
After skin contact
Wash off immediately with soap and water.
After eye contact
Separate eyelids, wash the eyes thoroughly with water (15 min.).
After ingestion
Seek medical advice immediately. Rinse mouth thoroughly with water. Never give anything by mouth to an unconscious person.
Fire-fighting measures Suitable extinguishing media
Foam; Carbon dioxide; extinguishing powder; Water spray jet
Special exposure hazards arising from the substance or preparation itself, combustion products, resulting gases
In the event of fire, the following can be released: Carbon dioxide (CO2) Carbon monoxide (CO) Fire gas of organic material has to be classed invariably as respiratory poison.
EC safety data sheet
Trade name: Bicalutamide 50 mg Film-coated tablets / Bicalutamide 150 mg Film
Special protective equipment for fire-fighters
Use self-contained breathing apparatus. Wear protective clothing.
Accidental release measures Personal precautions
Refer to protective measures listed in sections 7 and 8. Ensure adequate ventilation. Avoid dust formation. Keep away sources of ignition.
Environmental precautions
Do not discharge into the drains/surface waters/groundwater.
Methods for cleaning up/taking up
Pick up mechanically. When picked up, treat material as prescribed under heading "Disposal considerations".
Handling and storage Handling Advice on safe handling
No special measures necessary if stored and handled as prescribed. Avoid the formation and deposition of dust. Provide good ventilation of working area (local exhaust ventilation, if necessary).
Advice on protection against fire and explosion
Dust can form an explosive mixture with air. Take precautionary measures against static charges. Keep away from sources of heat and ignition.
Requirements for storage rooms and vessels Advice on storage assembly Further information on storage conditions
Keep container tightly closed and dry in a cool, well-ventilated place.
Exposure controls / personal protection Exposure limit values Personal protective equipment Respiratory protection
If workplace exposure limits are exceeded, a respiration protection approved for this particular job must be worn.
Hand protection
In case of intensive contact, wear protective gloves (EN 374). Sufficient protection is given wearing suitable protective gloves checked according to i.e. EN 374, in the event of risk of skin contact with the product . Before use, the protective glove should be tested in any case for its specific work-station suitability (i.e. mechanical resistance, product compatibility and antistatic properties). Adhere to the manufacturer’s instructions and information relating to the use, storage, care and replacement of protective gloves. Protective gloves shall be replaced immediately when physically damaged or worn. Design operations thus to avoid permanent use of protective gloves.
Eye protection Skin protection
Clothing as usual in the chemical industry.
General protective and hygiene measures
Do not eat, drink or smoke during work time. Keep away from foodstuffs and beverages. Wash hands before breaks and after work. Have eye wash fountain available. Do not inhale dust.
Physical and chemical properties General information Important health, safety and environmental information Solubility in water Octanol/water partition coefficient (log Pow) EC safety data sheet
Trade name: Bicalutamide 50 mg Film-coated tablets / Bicalutamide 150 mg Film
Stability and reactivity Conditions to avoid Materials to avoid Hazardous decomposition products
No hazardous decomposition products known.
Thermal decomposition Toxicological information Acute toxicity Acute oral toxicity Acute dermal toxicity Acute inhalational toxicity Effects after repeated or prolonged exposition (subacute, subchronic, chronic) Mutagenicity
In vitro mammalian cell gene mutation test
Reproduction toxicity
Indications of toxic effects are available from reproduction studies in animals.
Carcinogenicity
Indications of possible carcinogenic effects in animal studies are available.
Experience in practice Other information (chapter 11.)
The values mentioned are those of the active ingredient.
Ecological information Ecotoxicity Fish toxicity Daphnia toxicity Persistence and degradability Biodegradability Bioaccumulative potential Other adverse effects
Do not discharge product unmonitored into the environment. The ecological data given are those of the active ingredient.
Disposal considerations
Allocation of a waste code number, according to the European Waste Catalogue, should be carried out in agreement with the
EC safety data sheet
Trade name: Bicalutamide 50 mg Film-coated tablets / Bicalutamide 150 mg Film
Packaging
Residuals must be removed from packaging and when emptied completely disposed of in accordance with the regulations for waste removal. Incompletely emptied packaging must be disposed of in the form of disposal specified by the regional disposer.
Transport information Other information (chapter 14.)
The product is not defined under national/international road, rail, sea and air transport regulations as a hazardous material.
Regulatory information Labelling in accordance with EC directives
The product does not require a hazard warning label in accordance with EC Directive 1999/45/EC.
Hazard symbols Council Directive 96/82/EC on the control of major-accident hazards involving dangerous substances
Annex I, part 1 + 2: not mentioned. With regard to possibly appropriate decomposition products see Chapter 10.
Other information Sources of key data used to compile the data sheet:
EC Directive 67/548/EC resp. 99/45/EC as amended in each case. Regulation (EC) No 1907/2006 (REACH) as amended in each case. EC Directives 2000/39/EC, 2006/15/EC as amended in each case. National Threshold Limit Values of the corresponding countries as amended in each case. Transport regulations according to ADR, RID, IMDG, IATA as amended in each case. The data sources used to determine physical, toxic and ecotoxic data, are indicated directly in the corresponding chapter.
Department issuing safety data sheet
UMCO Umwelt Consult GmbH Georg-Wilhelm-Str. 183 b, D-21107 Hamburg Tel.: +49 40 / 41 92 13 00 Fax: +49 40 / 41 92 13 57 e-mail: umco@umco.de
This information is based on our present state of knowledge. However, it should not constitute a guarantee for any specific product properties and shall not establish a legally valid relationship.
TRAIL 17KM N°Dossard Catégorie 1 01:07:48 CA CAUCHOIS 2 01:07:48 3 01:07:48 AS MONTOISE 4 01:11:08 JEAN MICHEL sans club 5 01:11:40 CO BOLBEC 6 01:11:59 7 01:12:44 STEPHANE 8 01:12:51 HOLLEVILLE BERTRAND AMICAL NEUFCHATEL 9 01:13:10 AMICAL NEUFCHATEL 10 01:13:36 MACADAM ST NICOLAS 11 01:13:48 LAFLESSELLE sans club 12
Hepatitis B virus infections in families in which the Takegoshi Internal Medicine Clinic, 377-7 Nomura, Takaoka, Toyama 933-0014, Japan Department of Pathology, Tangdu Hospital, the Fourth Military Medical University, Xi’an, Shaanxi 710038, China Received 11 July 2005; received in revised form 10 November 2005; accepted 8 June 2006 Abstract We studied a total of 37 families, in wh